Industry Briefs

The EPA has incurred the wrath of the biotechnology industry with its draft of new biotech regulations. Both the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC) took a gander at the draft regulations at an EPA Biotechnology Science Advisory Committee meeting December 21 and promptly fired off press releases expressing their ire. The draft regulations - which were to be formally proposed at the end of January - represent a step backward for the EP

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The EPA has incurred the wrath of the biotechnology industry with its draft of new biotech regulations. Both the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC) took a gander at the draft regulations at an EPA Biotechnology Science Advisory Committee meeting December 21 and promptly fired off press releases expressing their ire. The draft regulations - which were to be formally proposed at the end of January - represent a step backward for the EPA and will be difficult for manufacturers to comply with, complained the Industrial Biotechnology Association. In an eight-page letter submitted to the EPA committee, the IBA criticizes the draft of proposed changes on a number of grounds, from its suggested creation of Environmental Biosafety Committees, made up of scientists and lay citizens to oversee biotechnology at the local level, to its definitions of "release to the environment" and "manufacturing."

For its part, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies